Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

20 та иш

Иш: The Role of Chemotherapy in Triple Negative Breast Cancer

  1. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

    Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard +7

    Мақола20075 иқтибос
    ABI

  2. Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy

    Brian D. Lehmann, Jennifer A. Pietenpol, Antoinette R. Tan

    Мақола20154 иқтибос
    ABI

  3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar, Lijun Zhang, Michael Untch +34

    Шарҳ мақола20144 иқтибос
    ABI

  4. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

    Brian D. Lehmann, Joshua A. Bauer, Xi Chen +4

    Мақола20114 иқтибос
    ABI

  5. Globocan 2000 : cancer incidence, mortality and prevalence worldwide

    Jacques Ferlay, Paola Pisani, Donald Maxwell Parkin

    Китоб20013 иқтибос
    ABI

  6. Molecular Subtype of Breast Cancer Metastases Significantly Influences Patient Post-Relapse Survival

    Nicholas P. Tobin, J. Chuck Harrell, Søren Brage +5

    Мақола20143 иқтибос
    ABI

  7. Pathological complete response in breast cancer – Authors' reply

    Patricia Cortazar, Charles E. Geyer, Luca Gianni +2

    Бошқа20153 иқтибос
    ABI

  8. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

    Gϋnter von Minckwitz, Michael Untch, Eveline Nüesch +20

    Мақола20103 иқтибос
    ABI

  9. Characteristics of triple-negative breast cancer

    Tim C. de Ruijter, Jürgen Veeck, Joep P.J. de Hoon +2

    Шарҳ мақола20103 иқтибос
    ABI

  10. Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors

    Valentina Guarneri, Kristine Broglio, Shu‐Wan Kau +8

    Мақола20063 иқтибос
    ABI

  11. Triple-Negative Breast Cancer: An Unmet Medical Need

    Clifford A. Hudis, Luca Gianni

    Шарҳ мақола20113 иқтибос
    ABI

  12. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

    Thérese Sørlie, Charles M. Perou, Robert Tibshirani +14

    Мақола20013 иқтибос
    ABI

  13. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

    Mark Ayers, W. Fraser Symmans, James Stec +15

    Мақола20043 иқтибос
    ABI

  14. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier, Charles M. Perou, W. Fraser Symmans +13

    Мақола20053 иқтибос
    ABI

  15. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gabriel N. Hortobágyi

    Мақола20123 иқтибос
    ABI

  16. Triple Negative Breast Cancer Pathologic Diagnosis and Current Chemotherapy Treatment Options

    Bernardo L. Rapoport, Simon Nayler, Georgia Demetriou +2

    Мақола20143 иқтибос
    ABI

  17. Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010-2011.

    Rebecca Dent, Paul N. Mainwaring, Tira J. Tan +4

    Мақола20153 иқтибос
    ABI

  18. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess +10

    Мақола20233 иқтибос
    ABI

  19. Gene expression profiling predicts clinical outcome of breast cancer

    Laura Van 't Veer, Hongyue Dai, Marc Van De Vijver +67

    Мақола20022 иқтибос
    ABI

  20. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI